Diagnostics And Consultation Center Convex Ltd.

Running trials

• Not yet recruiting

  A Biosimilar Trial to Investigate PK, PD, Safety With PB018 Versus US-licensed Ocrevus and EU-approved Ocrevus

  NCT07606521· Phase 1· Source

• Recruiting

  A Phase IIb Study to Evaluate AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

  2025-525016-41-00· Phase 2· Source

• Recruiting

  Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

  NCT07626411· Phase 3· Source

• Recruiting

  A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis

  NCT07725939· Phase 2· Source

• Recruiting

  A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma

  NCT07532265· Phase 2· Source

• Recruiting

  Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease

  NCT07318610· Phase 3· Source

• Recruiting

  A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis

  NCT07516951· Phase 2· Source

• Recruiting

  BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg])

  NCT07666490· Phase 4· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· Phase 3· Source

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Source

• Recruiting

  Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes

  NCT07216235· Phase 3· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

  NCT07067463· Phase 3· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

  NCT07299019· Phase 3· Source

• Recruiting

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  NCT07361510· Phase 3· Source

• Not yet recruiting

  A study to assess the safety and efficacy of different doses of ELV001 to treat active rheumatoid arthritis in patients with an inadequate response to methotrexate and tumor necrosis factor inhibition (START SYNERGY)

  2025-524005-32-00· Phase 2· Source

• Recruiting

  A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

  NCT06968845· Phase 2· Source

• Recruiting

  Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis

  NCT07230288· Phase 2· Source

• Recruiting

  Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

  NCT07325292· Phase 3· Source

• Recruiting

  A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)

  NCT07276724· Phase 3· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)

  2024-516654-22-00· Phase 3· Source

• Active, not recruiting

  Trial of Sibeprenlimab in the Treatment of Sjögren’s Disease

  2024-516295-14-00· Phase 2· Source

• Recruiting

  Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma

  NCT07120503· Phase 2· Source

• Recruiting

  Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

  NCT06961214· Phase 3· Source

• Active, not recruiting

  Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis

  NCT06847724· Phase 3· Source

• Active, not recruiting

  A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)

  NCT06966479· Phase 2· Source

• Recruiting

  Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure

  NCT06929806· Phase 3· Source

• Recruiting

  Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  NCT07032662· Phase 2· Source

• Active, not recruiting

  A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma

  NCT06748053· Phase 2· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis

  NCT06754462· Phase 2· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared with Placebo Added to Standard of Care in Adult Participants with Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

  2023-504022-19-01· Phase 3· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

  NCT06655155· Phase 2· Source

• Active, not recruiting

  A Phase 2 Study of Obexelimab in Patients with Systemic Lupus Erythematosus

  2024-510584-37-00· Phase 2· Source

• Recruiting

  Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis

  2023-504358-36-00· Phase 3· Source

• Active, not recruiting

  Phase IIa Study Evaluating AZD7798 in Crohn's Disease

  NCT06450197· Phase 2· Source

• Active, not recruiting

  Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

  NCT06141486· Phase 3· Source

• Active, not recruiting

  A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

  NCT06052267· Phase 3· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Source

• Active, not recruiting

  Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

  NCT05639114· Phase 3· Source

• Active, not recruiting

  A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05528510· Phase 3· Source

• Active, not recruiting

  Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

  NCT05147220· Phase 3· Source

• Active, not recruiting

  A Study of Guselkumab in Participants With Active Psoriatic Arthritis

  NCT04882098· Phase 3· Source

• Recruiting

  A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.

  NCT04752774· Phase 1/2· Source

• Active, not recruiting

  A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)

  NCT04280718· Phase 2· Source

• Active, not recruiting

  A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT04033445· Phase 2/3· Source

• Active, not recruiting

  An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

  NCT03950232· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Asthma4 recruiting
• Idiopathic pulmonary fibrosis4 recruiting
• Multiple sclerosis4 recruiting
• Heart failure3 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)2 recruiting
• COPD2 recruiting
• Lung cancer2 recruiting
• Obesity2 recruiting
• Atrial fibrillation1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Peripheral artery disease1 recruiting
• Primary biliary cholangitis1 recruiting
• Rheumatoid arthritis1 recruiting
• Stroke1 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A study to investigate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn’s disease or ulcerative colitis

  NCT07222189· Phase 2· Source

• Recruiting

  A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

  NCT06920004· Phase 3· Source

• Completed

  Safety, Tolerability, and Efficacy of NVG-2089 in Participants with CIDP

  2024-515386-34-00· Phase 2· Source

• Completed

  A study to investigate efficacy and safety of SAR441566 in patients with Crohn's disease.

  NCT06637631· Phase 2· Source

• Not yet recruiting

  A Study to Investigate Using Inhaled Fexlamose to Treat Adult Participants Who Have Moderate to Severe COPD

  NCT06731959· Phase 2· Source

• Completed

  A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome

  NCT06312020· Phase 2· Source

• Completed

  A Phase 1b, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB310 in Patients with Active, Mild to Moderate Ulcerative Colitis (COMPOSER-1)

  2023-507376-50-00· Phase 1· Source

• Completed

  A Phase 2, Double-blind, Placebo-controlled, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma

  NCT06376045· Phase 2· Source

• Completed

  A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)

  NCT06920771· Phase 3· Source

• Completed

  Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis

  2023-508679-34-00· Phase 2· Source

• Completed

  A study to investigate the safety, tolerability, and pharmacokinetics of Ent001 in patients with moderately to severely active ulcerative colitis

  2023-507340-36-00· Phase 1· Source

• Completed

  A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

  NCT06323928· Phase 2· Source

• Completed

  A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension

  NCT06168409· Phase 3· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)

  NCT06196879· Phase 2· Source

• Completed

  Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction

  NCT06017609· Phase 2· Source

• Completed

  Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS).

  NCT06264674· Phase 3· Source

• Completed

  A Phase 2 study to evaluate the efficacy and safety of RPT193 in adults with moderate-to-severe T2-high asthma who are partially controlled on inhaled corticosteroid and long-acting beta 2 agonist therapy

  2022-502854-16-00· Phase 2· Source

• Completed

  Efficacy and safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund maintenance therapy

  2022-502208-64-00· Phase 2· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

  NCT06034743· Phase 3· Source

• Completed

  A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

  NCT05798520· Phase 2· Source

• Completed

  Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis

  NCT05672199· Phase 2· Source

• Completed

  ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

  NCT05507216· Phase 3· Source

• Completed

  A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

  NCT05595642· Phase 3· Source

• Completed

  A Phase 2 double-blind, randomized, placebo-controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participants with multiple sclerosis, followed by an open-label long-term extension period

  2023-509078-45-00· Phase 2· Source

• Completed

  A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD

  NCT04320342· Phase 3· Source

• Completed

  Safety and Efficacy of Efavaleukin Alfa in Subjects with Moderately to Severely Active Ulcerative Colitis

  NCT04987307· Phase 2· Source

• Active, not recruiting

  Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis

  NCT05138133· Phase 3· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Source